Some patients may benefit from systemic therapy

Person depicted is not an actual patient.

While resection may be an option, recurrence is always a possibility.

Consider if TURALIO is an appropriate option for your patients1

Maximize outcomes in TGCT by evaluating treatment considerations together with your patients

Tumor type:
localized or diffuse
Tumor
resectability
Expected outcome
of treatment
Patient
age
Joint
worsening
Patient
comorbidities

Consider these important factors when thinking about which of your patients may benefit from TURALIO

PATIENT ID TOOL

People depicted are not actual patients.

People depicted are not actual patients.

Downloadable resources to learn more about treatment with TURALIO

Decision Worksheet Patient Brochure

Understanding the multidisciplinary team (MDT)

A comprehensive MDT is crucial for your patient’s potential success. This team may include:

OncologistsEven though TGCT is typically non-malignant, oncologists provide a valued contribution to the long-term management of patients with recurrent, diffuse, or difficult-to-treat TGCT. They may help provide treatment options beyond surgery.

Advanced practitionersNurse practitioners and physician assistants are trained to help treat complex and difficult diseases like TGCT.

Orthopedic surgeonsSince surgical resection is the standard of care for TGCT, orthopedic surgeons can play an important role in the long-term management of patients with TGCT.

People depicted are not actual HCPs.

Having a well-rounded team may help you treat your patients with TGCT in a comprehensive and successful manner

Learn about the ENLIVEN trial design
STUDY DESIGN

Interested in TURALIO?

Get more information and resources

SIGN UP FOR UPDATES Mobi Signup

References: 1. Ehrenstein V et al. J Rheumatol. 2017;44(10):1476-1483.